

One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

Authors:

Olivia C Leavy*^{1,2}, Richard J Russell*², Ewen M Harrison³, Nazir I Lone^{4,5}, Steven Kerr^{6,3}, Annemarie B Docherty³, Aziz Sheikh⁴, Matthew Richardson², Omer Elneima², Neil J Greening², Victoria Claire Harris^{2,7}, Linzy Houchen-Wolloff^{8,9,10}, Hamish J C McAuley², Ruth M Saunders², Marco Sereno², Aarti Shikotra¹¹, Amisha Singapuri², Raminder Aul¹², Paul Beirne¹³, Charlotte E Bolton^{14,15,16}, Jeremy S Brown¹⁷, Gourab Choudhury^{18,19}, Nawar Diar Bakerly^{20,21}, Nicholas Easom^{22,23}, Carlos Echevarria^{24,25}, Jonathan Fuld^{26,27,28}, Nick Hart²⁹, John R Hurst^{30,31}, Mark Jones^{32,33}, Dhruv Parekh^{34,35}, Paul Pfeffer^{36,37}, Najib M Rahman^{38,39,40,41}, Sarah Rowland-Jones^{42,43}, Ajay M Shah^{44,45}, Dan G Wootton^{46,47,48}, Caroline Jolley^{44,45}, AA Roger Thompson^{42,43}, Trudie Chalder^{49,50}, Melanie J Davies^{51,11,7}, Anthony De Soyza^{52,53}, John R Geddes^{54,55}, William Greenhalf^{56,57,47}, Simon Heller⁵⁸, Luke Howard^{59,60}, Joseph Jacob^{61,62}, R Gisli Jenkins⁶³, Janet M Lord^{64,65}, Will D-C Man^{66,67}, Gerry P McCann^{68,11}, Stefan Neubauer^{69,54}, Peter JM Openshaw⁶³, Joanna Porter^{17,70}, Matthew J Rowland⁷¹, Janet T Scott⁷², Malcolm G Semple^{73,74}, Sally J Singh², David Thomas⁶⁰, Mark Toshner^{75,28}, Keir Lewis^{76,77,78}, Liam G Heaney^{79,80}, Andrew Briggs⁸¹, Bang Zheng⁸¹, Mathew Thorpe³, Jennifer K Quint⁶⁷, James D Chalmers⁸², Ling-Pei Ho^{83,40}, Alex Horsley^{84,85}, Michael Marks^{86,87,88}, Krisnah Poinasamy⁸⁹, Betty Raman^{90,38}, Louise V Wain^{1,2}, Christopher E Brightling², Rachael A Evans^{2,7}, on behalf of the PHOSP-COVID Collaborative Group

¹Department of Population Health Sciences, University of Leicester, Leicester, UK, ²The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK, ³Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK, ⁴The Usher Institute, University of Edinburgh, Edinburgh, UK, ⁵Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK, ⁶Roslin Institute, University of Edinburgh, Edinburgh, UK, ⁷University Hospitals of Leicester NHS Trust, Leicester, UK, ⁸Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK, ⁹Department of Respiratory Sciences, University of Leicester, Leicester, UK, ¹⁰Therapy Department, University Hospitals of Leicester, NHS Trust, Leicester, UK, ¹¹NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK, ¹²St Georges University Hospitals NHS Foundation Trust, London, UK, ¹³The Leeds Teaching Hospitals NHS Trust, Leeds, UK, ¹⁴University of Nottingham, Nottingham, UK, ¹⁵Nottingham University Hospitals NHS Trust, Nottingham, UK, ¹⁶NIHR Nottingham Biomedical Research Centre, Nottingham, UK, ¹⁷UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK, ¹⁸University of Edinburgh, Edinburgh, UK, ¹⁹NHS Lothian, Edinburgh, UK, ²⁰Manchester Metropolitan University, Manchester, UK, ²¹Salford Royal NHS Foundation Trust, Manchester, UK, ²²Infection Research Group, Hull University Teaching Hospitals, Hull, UK, ²³University of Hull, Hull, UK, ²⁴The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK, ²⁵Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK, ²⁶Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, ²⁷University of Cambridge, Cambridge, UK, ²⁸NIHR Cambridge Clinical Research Facility, Cambridge, UK, ²⁹Lane Fox Respiratory Service, Guys and St Thomas NHS Foundation Trust, London, UK, ³⁰University College London, London, UK, ³¹Royal Free London NHS Foundation Trust, London, UK, ³²Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK, ³³NIHR Southampton Biomedical Research Centre, University Hospitals Southampton, Southampton, UK, ³⁴University of Birmingham, Birmingham, UK, ³⁵University Hospital Birmingham NHS Foundation Trust, Birmingham, UK, ³⁶Barts Health NHS Trust, London, UK,

³⁷Queen Mary University of London, London, UK, ³⁸Oxford University Hospitals NHS Foundation Trust, Oxford, UK, ³⁹University of Oxford, Oxford, UK, ⁴⁰NIHR Oxford Biomedical Research Centre, Oxford, UK, ⁴¹CAMS Oxford Institute, Oxford, UK, ⁴²University of Sheffield, Sheffield, UK, ⁴³Sheffield Teaching NHS Foundation Trust, Sheffield, UK, ⁴⁴Kings College London, London, UK, ⁴⁵Kings College London NHS Foundation Trust, London, UK, ⁴⁶Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK, ⁴⁷Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK, ⁴⁸NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK, ⁴⁹Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK, ⁵⁰South London and Maudsley NHS Trust, London, UK, ⁵¹Diabetes Research Centre, University of Leicester, Leicester, UK, ⁵²Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK, ⁵³Newcastle upon Tyne Teaching Hospitals Trust, Newcastle upon Tyne, UK, ⁵⁴NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK, ⁵⁵Oxford Health NHS Foundation Trust, Oxford, UK, ⁵⁶University of Liverpool, Liverpool, UK, ⁵⁷The CRUK Liverpool Experimental Cancer Medicine Centre, Liverpool, UK, ⁵⁸Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK, ⁵⁹Imperial College Healthcare NHS Trust, London, UK, ⁶⁰Imperial College London, London, UK, ⁶¹Centre for Medical Image Computing, University College London, London, UK, ⁶²Lungs for Living Research Centre, University College London, London, UK, ⁶³National Heart and Lung Institute, Imperial College London, London, UK, ⁶⁴MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, ⁶⁵NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham and the University of Birmingham, Birmingham, UK, ⁶⁶Royal Brompton and Harefield Clinical Group, Guys and St Thomas NHS Foundation Trust, London, UK, ⁶⁷NHLI, Imperial College London, London, UK, ⁶⁸Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, ⁶⁹Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK, ⁷⁰ILD Service, University College London Hospital, London, UK, ⁷¹Kadoorie Centre for Critical Care Research, Nuffield Department of

Clinical Neurosciences, University of Oxford, Oxford, UK, ⁷²MRC-University of Glasgow Centre for Virus Research, Glasgow, UK, ⁷³NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK, ⁷⁴Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK, ⁷⁵Cambridge NIHR BRC, Cambridge, UK, ⁷⁶Hywel Dda University Health Board, Wales, UK, ⁷⁷University of Swansea, Wales, UK, ⁷⁸Respiratory Innovation Wales, Wales, UK, ⁷⁹Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK, ⁸⁰Belfast Health & Social Care Trust, Belfast, UK, ⁸¹London School of Hygiene & Tropical Medicine, London, UK, ⁸²University of Dundee, Ninewells Hospital and Medical School, Dundee, UK, ⁸³MRC Human Immunology Unit, University of Oxford, Oxford, UK, ⁸⁴Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, ⁸⁵Manchester University NHS Foundation Trust, Manchester, UK, ⁸⁶Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK, ⁸⁷Hospital for Tropical Diseases, University College London Hospital, London, UK, ⁸⁸Division of Infection and Immunity, University College London, London, UK, ⁸⁹Asthma and Lung UK, London, UK, ⁹⁰Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

***joint first authors**

Corresponding author:

Dr Rachael Evans

re66@leicester.ac.uk

NIHR Respiratory BRC, Glenfield Hospital, Groby Rd, Leicester, UK. LE3 9QP

+44 116 258 3663

Take home message:

Systemic corticosteroids given for acute COVID-19 do not affect health-related quality of life or other patient reported outcomes, physical and mental health outcomes, and organ function one year after hospital discharge

Keywords:

Corticosteroids

COVID-19

Long Covid

EQ-5D-5L

Health-related quality of life

Word counts:

Abstract: 250 words

Manuscript: 3000 words

Abstract

Background

In patients with COVID-19 requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during acute COVID-19 would be associated with improved health-related quality of life (HRQoL) one year after discharge.

Methods

Adults admitted to hospital between February 2020 and March 2021 for COVID-19 and meeting current guideline recommendations for dexamethasone treatment were included using two prospective UK cohort studies. HRQoL, assessed by EQ-5D-5L utility index, pre-hospital and one year after discharge were compared between those receiving corticosteroids or not after propensity weighting for treatment. Secondary outcomes included patient reported recovery, physical and mental health status, and measures of organ impairment. Sensitivity analyses were undertaken to account for survival and selection bias.

Findings

In 1,888 participants included in the primary analysis, 1,149 received corticosteroids. There was no between-group difference in EQ-5D-5L utility index at one year (mean difference 0.004, 95% CI: -0.026 to 0.034, $p = 0.77$). A similar reduction in EQ-5D-5L was seen at one year between corticosteroid exposed and non-exposed groups (mean (SD) change -0.12 (0.22) vs -0.11 (0.22), $p = 0.32$). Overall, there were no differences in secondary outcome measures. After sensitivity analyses modelled using a larger cohort of 109,318 patients admitted to hospital with COVID-19, EQ-5D-5L utility index at one year remained similar between the two groups.

Interpretation

Systemic corticosteroids for acute COVID-19 have no impact on the large reduction in HRQoL one year after hospital discharge. Treatments to address this are urgently needed.

Introduction

The discovery of vaccines and effective treatments for acute COVID-19 (corticosteroids [dexamethasone], anti-interleukin (IL)-6 agents, monoclonal antibodies and Janus kinase inhibitors) have reduced progression to invasive mechanical ventilation and improved mortality [1-4]. However, many survivors experience persistent symptoms, physical and mental health effects, cognitive impairment, and multi-system organ damage, which can reduce health-related quality of life (HRQoL) for years after the initial infection [5-7].

Definitions for post-COVID-19 sequelae vary [8, 9], but the patient-derived term ‘Long Covid’ is now commonly used to describe persistent symptoms beyond four weeks after the acute infection [10]. The mechanisms underlying Long Covid are complex, multifaceted, and not yet fully understood, but potentially include persistent inflammation, which is associated with the severity of ongoing health impairments [5, 11]. Corticosteroids prescribed for acute COVID-19 may potentially reduce the risk and severity of Long Covid by attenuating the acute inflammatory burden.

Many of the large acute COVID-19 therapeutic trials including RECOVERY [1-4] did not have detailed follow-up, which limits understanding of the longer-term effects, and it would now be unethical to randomise patients to placebo rather than corticosteroids. Adults previously randomised to receive acute corticosteroids on intensive care showed no improvement in HRQoL at six months compared to usual care [12], and we previously reported no acute corticosteroid effect on patient perceived recovery at one year[6]. However, it is unknown whether corticosteroids during acute COVID-19 affect other longer-term sequelae.

Using data from the PHOSP-COVID (Post-hospitalisation COVID-19 study) [13] and ISARIC (International Severe Acute Respiratory and emerging Infection Collaboration) [14] studies, we aimed to investigate whether treatment with corticosteroids in patients with COVID-19 requiring oxygen supplementation was associated with improved HRQoL one year after hospital discharge. Additionally, we aimed to investigate the effect of acute corticosteroids on a broad range of secondary health outcomes.

Methods

Study design

This was a longitudinal cohort study using data from two UK multicentre prospective cohort studies. Adults discharged from hospital after COVID-19 between 1st February 2020 and 31st March 2021 were recruited from 36 UK National Health Service (NHS) hospital sites as part of the PHOSP-COVID study previously described [13]. Data were collected one year after hospital discharge, including patient reported recovery, physical and mental health status, and measures of organ impairment (detailed below). Pre-hospital EuroQol five-dimension five-level utility index (EQ-5D-5L UI) was completed retrospectively at a study visit 2-7 months after hospital discharge, with participants considering their quality of life prior to admission for COVID-19.

For the sensitivity analysis, we used data from the ISARIC (UK) study [14], which included more than 300,000 patients admitted to over 200 NHS hospitals across England, Scotland and Wales with COVID-19.

Participants

Eligibility criteria for PHOSP-COVID have been previously described in detail [13]. For this analysis we selected participants who required supplemental oxygen therapy (WHO clinical progression scale 5), non-invasive ventilatory support (WHO clinical progression scale 6), or invasive mechanical ventilation (WHO clinical progression scale 7-9) [15] during their hospital admission in accordance with current guideline requirements for corticosteroid use in COVID-19 [16], and who had completed an EQ-5D-5L UI at their one year study visit. We excluded patients on pre-existing immunosuppressant medications, and where corticosteroid exposure was unknown or not recorded (Figure 1).

For the sensitivity analysis, we analysed a subset of the ISARIC study cohort, who were admitted with COVID-19 in the same study period and meeting the same WHO clinical progression scale criteria [14] (Figure 1).

Exposure

Patients who received any systemic (oral or intravenous) corticosteroid during their hospital admission for COVID-19 were compared to those who did not.

Outcomes

The primary outcome was HRQoL, assessed by EQ-5D-5L UI [17]. EQ-5D-5L one year after hospital discharge, and change in EQ-5D-5L UI from pre-hospital to one year, were compared between corticosteroid exposed and non-exposed patients.

Secondary outcomes were patient perceived recovery (patient reported recovery rate, symptom count, fatigue visual analogue scale (VAS), breathlessness VAS), physical health status (dyspnoea-12 score [18], Functional Assessment of Chronic Illness Therapy (FACIT) fatigue score [19], Washington Group Short Set on Functioning (WG-SS) score [20], incremental shuttle walk

test (ISWT) distance [21], short physical performance battery (SPPB) score [22]), mental health status (Montreal Cognitive Assessment (MoCA) score [23], Generalised Anxiety Disorder (GAD)-7 score [24], Patient Health Questionnaire (PHQ)-8 score [25], Post-traumatic Stress Disorder Checklist (PCL)-5 score [26]), and organ function (forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, carbon monoxide transfer coefficient (KCO), transfer factor of the lung for carbon monoxide (TLCO), brain-natriuretic peptide (BNP), haemoglobin A1c (HbA1c), estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), fibrinogen).

Bias

Several potential sources of bias were considered *a priori*; (i) *treatment bias* by clinician prescribing decision (prior to corticosteroids becoming standard care in June 2020), (ii) *selection bias* regarding who participated in the PHOSP-COVID study, and (iii) *survivor bias* due to participants being recruited to PHOSP-COVID after hospital discharge (i.e., survivors). A statistical analysis plan was developed including the use of propensity weighting to ensure balance between treatment groups in the primary analysis, and sensitivity analyses using data from the ISARIC study.

Statistical analysis

The main analysis was undertaken using the PHOSP-COVID cohort. A logistic regression model was fitted to estimate propensity for exposure to corticosteroids. An average treatment effect of corticosteroid treatment on the outcomes (primary and secondary) was calculated weighted by the inverse of propensity for exposure using either linear or logistic regression, depending on the distribution of the outcome. The following variables, which potentially influence treatment

decisions, were included in the propensity model: age, sex, obesity status, ethnicity, Index of Multiple Deprivation, WHO Clinical Progression Scale status, smoking status, presence of specific comorbidities (cardiovascular, respiratory, metabolic/endocrine/renal, neurological/psychiatric) and total number of comorbidities. Multiple Imputation by Chained Equations (MICE) was performed to deal with missing data for the variables used in the propensity model. Summary statistics tables were produced for patients by exposure status, visually inspecting the distribution of propensity scores and evaluating imbalance between groups by standardised mean difference (SMD).

Sensitivity analyses

Sensitivity analyses were performed using the ISARIC (UK) dataset to address selection, treatment and survivor biases in PHOSP-COVID (supplementary methods). In summary, a propensity score weighting for corticosteroid treatment was developed in the ISARIC (UK) cohort (survivors and non-survivors) using logistic regression. The PHOSP-COVID dataset was used to develop a prediction model for EQ-5D-5L UI at one year. We used this model to calculate predicted one-year EQ-5D-5L UI values for those that survived COVID-19 hospitalisation in the ISARIC cohort (1000 estimates per patient). Adults that did not survive were assigned an EQ-5D-5L value of zero. Participants who were in both ISARIC and PHOSP-COVID cohorts were assigned their PHOSP-COVID EQ-5D-5L value. The 1000 datasets created were sub-sampled down to the PHOSP-COVID dataset size to ensure robust standard errors (1000 random samples of each dataset). These datasets were used to produce an average treatment effect of corticosteroid exposure on EQ-5D-5L UI weighted by the inverse of propensity for exposure using linear regression.

The sensitivity analysis addressed selection and survivor bias by using the structure of the ISARIC population (assuming the ISARIC population was similar to all hospitalised patients with COVID-

19 eligibility to receive corticosteroids). The ISARIC cohort included participants who did not survive hospitalisation with COVID-19. Biased treatment assignment was accounted for by developing a propensity score with corticosteroid as the dependent variable, which was developed in the ISARIC cohort, and was therefore independent of survival status at hospital discharge.

Statistical analysis was undertaken using R (version 4.2.0) with the *tidyverse*, *tidymodels*, *mice*, *finalfit*, *WeightIt*, and *tableone* packages for all statistical analyses. The study is reported using the STROBE reporting guidelines.

Permissions

PHOSP-COVID was approved by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the ISRCTN Registry (ISRCTN10980107). ISARIC was approved by the South Central - Oxford C Research Ethics Committee in England and the Scotland A Research Ethics Committee.

Results

The relevant PHOSP-COVID cohort consisted of 2,697 participants, of whom 2,248 required at least supplemental oxygen and were discharged from hospital between 1st February 2020 and 31st March 2021. There were 1,888 participants with non-missing corticosteroid information not prescribed immunosuppressant medication pre-hospital, of which 1,149 (60.9%) were corticosteroid exposed, and 739 (39.1%) were corticosteroid non-exposed. 1,226 participants had an EQ-5D-5L UI score at their one-year visit and 1,057 participants had both pre-hospital and one-year EQ-5D-5L UI scores (Figure 1).

Baseline characteristics for the 1,888 included participants demonstrated a mean age of 58.6 years with 64.4% being male. 75.1% were White, 10.1% South Asian, 7.3% Black, and 7.5% other ethnicity. 58.6% were obese (body mass index $\geq 30\text{kg/m}^2$), and 43.8% had two or more comorbidities (Table S1). Prior to propensity weighting some baseline characteristics were imbalanced between treatment groups, as demonstrated by an SMD of >0.1 (Table S1). Participants treated with corticosteroids were slightly younger compared to those not receiving corticosteroids (58.0 vs 59.7 years), and had greater prevalence of: White ethnicity (76.8% vs 72.5%), deprivation (49.5% vs 41.0% in lowest two deprivation index quintiles), and obesity (61.0% vs 55.8%). The corticosteroid group had a lower proportion of ‘never smokers’ (54.9% vs 56.4%). There were also differences in the level of respiratory support required between patients treated with corticosteroid and those not: 51.5% vs 54.7% received low-flow oxygen (WHO scale 5), 33.3% vs 22.6% received non-invasive respiratory support (WHO scale 6), 15.1% vs 22.7% received invasive mechanical ventilation (WHO scale 7-9).

Propensity weighting successfully achieved balance between the treatment groups, as demonstrated by a SMD <0.1 for all recorded baseline outcomes (Table 1).

Primary outcomes

After propensity weighting for treatment there was no statistically significant difference in EQ-5D-5L UI at one year between corticosteroid exposed (mean (SD) 0.72 (0.25)) and non-exposed (0.71 (0.25)) groups (mean difference 0.004, 95% CI: -0.026 to 0.034, $p = 0.77$) (Table 2 and Figures 2 and 3).

There was a large reduction in EQ-5D-5L UI from pre-hospital to one year, with no significant difference between corticosteroid exposed (mean change -0.12 (0.22)) and non-exposed (-0.11 (0.22)) groups (mean difference 0.01, 95% CI: -0.01 to 0.04, $p = 0.32$) (Table 2 and Figure 3).

Secondary outcomes

Secondary outcomes, assessing patient reported outcomes, physical, cognitive and mental health status, and measurements of organ impairment, were not significantly different between treatment groups at one year (Tables 2 and 3, and Figure 4), except breathlessness VAS which was lower in patients who had received corticosteroids (median [IQR] 1.0 [0.0, 4.0] vs 1.0 [0.0, 5.0], $p = 0.043$).

Sensitivity analysis

In the sensitivity analysis, there was no significant difference in the EQ-5D-5L at one year between patients who received corticosteroids and those who did not (between group difference 0.021, 95% CI: -0.033 to 0.074, $p = 0.45$) (Figure 2).

Discussion

To our knowledge this is the first report investigating the effect of acute corticosteroids on HRQoL, other patient reported outcomes, physical and mental health status, and multi-system organ effects one year after hospitalisation for COVID-19. We observed large reductions in HRQoL at one year and report novel findings that there was neither a difference in EQ-5D-5L UI at one year, nor in EQ-5D-5L change pre-hospital to one year, between patients who did or did not receive corticosteroids for their acute illness. There remained no difference in HRQoL at one year after adjusting for survivor and selection bias using a large cohort of patients admitted with COVID-19

(ISARIC cohort). We also found no difference between receipt of acute corticosteroids or not across a range of secondary endpoints assessing patient reported outcomes, physical, cognitive and mental health status, and measurements of multi-system organ impairment. Despite the observational longitudinal nature of our study, it is likely to be the most comprehensive and robust data available, as the large acute randomised controlled trials of therapeutics in COVID-19 were unable to perform in-person follow-up assessments [1-4], and corticosteroids are now standard of care for COVID-19, meaning a placebo-controlled trial would now be unethical [16]. Our recruitment period encompassed time before and after systemic corticosteroids became standard care for patients requiring oxygen due to COVID-19 (June 2020), allowing comparison between corticosteroid exposed and non-exposed groups.

Our data demonstrate the significant negative impact on HRQoL and other health outcomes one year after hospital discharge in this population, similar to our previous reports but in a larger subset [6]. Pre-hospital our cohort reported EQ-5D-5L UI scores in line with normal values (reported as 0.81 for men and 0.79 for women aged 55-59 years) [27]. One year after discharge from hospital, the EQ-5D-5L UI was comparable to long-term health conditions such as COPD [28].

Developments in treatments for acute COVID-19 (including pharmacological therapies, such as corticosteroids, and ventilation strategies), combined with effective vaccines, have significantly reduced the risk of in-hospital COVID-19 mortality. However, the risk of Long Covid remains, and although risk increases with more severe acute illness [5], many people with mild acute COVID-19 develop persistent health problems. We have previously shown that elevated inflammatory proteins five months after COVID-19 hospital discharge are associated with increased risk of very severe health impairments at one year [5], therefore it was reasonable to hypothesize that the anti-inflammatory effect of corticosteroids could mitigate the risk of Long

Covid. A previous study found no difference in HRQoL 180 days after hospital discharge from a higher 12mg dose of dexamethasone compared to the standard 6mg dose [29], but HRQoL comparisons between corticosteroid treated or not were not available.

Other acute pharmacological interventions have shown promising effects on the risk of Long Covid. Anti-IL6 (tocilizumab) improves HRQoL at six months in COVID-19 survivors admitted to intensive care [12], although whether this benefit applies to patients outside of intensive care is unknown. The anti-viral remdesivir is associated with a reduction in rates of Long Covid at 180 days, although the study excluded severely unwell patients so this benefit may not apply to a broader population [30]. *Post-hoc* analysis of nebulised interferon-beta-1a for COVID-19 showed reductions in fatigue/malaise and loss of taste or smell at 60-90 days compared to placebo, and further investigation is ongoing [31]. Metformin reduces the risk of Long Covid in non-hospitalised overweight and obese patients, although the effect in more severe disease is unknown [32]. While the results of these trials are encouraging, it is noteworthy that each has limitations to their applicability in a wider patient population, and none have provided strong enough evidence to change treatment guidelines with the aim of reducing Long Covid. The HEAL-COVID study reported no benefit from 2 weeks of anticoagulation (apixaban) on post-discharge mortality or hospital readmission but has not yet reported quality of life outcomes [33]. A second study arm investigating 12 months of atorvastatin is underway [34].

Trials of potential treatments for patients with persistent health problems beyond the acute COVID-19 illness are being undertaken, although are few in number. In a phase 2 placebo-controlled trial, 4 weeks of AXA1125 (an endogenous metabolic modulator comprised of five amino acids and N-acetylcysteine) improved fatigue scores in patients with persistent fatigue at least 12 weeks after COVID-19 [35]. The Stimulate-ICP (Symptoms, Trajectory, Inequalities and

Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study will investigate the effect of antihistamine (famotidine/loratidine), anticoagulation (rivaroxaban), and anti-inflammatory (colchicine) medications on Long Covid recovery, in addition to interventions such as rehabilitation strategies [36]. The PHOSP-I study will investigate tocilizumab in patients with persistent symptoms at least 3 months after COVID-19 and evidence of persistent systemic inflammation [37]. Given the evidence for acute interventions not reducing Long Covid across a broad patient population, these trials and others are urgently needed to reduce post-covid sequelae including Long Covid.

Our study has a number of strengths. We included a large cohort of patients discharged from hospital after receiving oxygen for COVID-19, and our sensitivity analysis uses ISARIC data to verify our findings in a much larger hospitalised cohort also requiring oxygen. Therefore, we are confident that our findings are applicable to patients meeting guideline criteria for corticosteroid treatment for COVID-19. Additionally, we used propensity weighting to ensure balance between groups prior to analysing one-year outcomes, in an attempt to replicate the effect of randomised allocation and account for elements of biasing. We are confident, therefore, that the lack of benefit from acute corticosteroids observed here is genuine.

Our study has some limitations. First, despite using propensity weighting methods, this is an observational study and therefore unable to fully replicate a randomised trial. Our statistical methods were designed to minimise potential biases related to this, but some residual effect may remain. Second, we included patients admitted to hospital over a 14-month period, spanning waves of different covid variants, and the early stages of the vaccine rollout. We cannot exclude potential effects due to these factors, particularly as our corticosteroid non-exposed participants were predominantly hospitalised before June 2020, and corticosteroid exposed participants

predominantly after June 2020. Third, the PHOSP-COVID cohort had a more severe acute illness than the general hospitalised COVID-19 population, and only includes patients who survived at least 5 months after discharge, and is therefore subject to selection and survivor biases. We have attempted to address these in our sensitivity analysis, using the ISARIC cohort which includes patients who died. Fourth, there is a significant amount of missing lung function data, due to variable infection prevention restrictions during the study period. Therefore, we cannot fully exclude a possible effect on lung function. Finally, pre-hospital EQ-5D-5L was assessed retrospectively using patient recollection of their quality of life prior to hospitalisation with COVID-19. These data are therefore subject to recall bias, although the effect is likely equal between the treatment groups.

There remains a large reduction in HRQoL, and other health outcomes, one year after hospitalisation for COVID-19. Studies to identify pharmacological and non-pharmacological interventions given after the acute COVID-19 illness are essential to address this. It is also important to seek better mechanistic understanding of post-covid sequelae and improve phenotyping of patients who may respond to specific interventions.

In conclusion, we found no long-term benefit on HRQoL from corticosteroids given to treat acute COVID-19. There remains an urgent need for effective interventions that reduce the long-term burden of health issues following COVID-19.

Funding

PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Data access

The PHOSP-COVID study website (<https://www.phosp.org>) contains an overview of the study, resources, information about people involved, and publications. Research activity using the study is organised across a series of Working Groups. These were established at the outset of the study to coordinate research, minimise duplication of efforts, and facilitate communication across research and clinical specialties. Researchers interested in undertaking research using PHOSP-COVID are encouraged to contact the relevant Working Group leads (<https://www.phosp.org/working-group/>) in the first instance. The data are currently held in the Outbreak Data Analysis Platform (ODAP, <https://odap.ac.uk/>). Researchers seeking to access these data are directed to <https://www.phosp.org/resource/> for information and forms. Correspondence to be directed to Dr Rachael A Evans, the Co-Principal Investigator of PHOSP-COVID study phosp@leicester.ac.uk.

Acknowledgements

This study would not be possible without all the participants who have given their time and support. We thank all the participants and their families. We thank the many research administrators, health-care and social-care professionals who contributed to setting up and delivering the study at all of the 65 NHS trusts/Health boards and 25 research institutions across the UK, as well as all the supporting staff at the NIHR Clinical Research Network, Health Research Authority, Research Ethics Committee, Department of Health and Social Care, Public Health Scotland, and Public Health England, and support from the ISARIC Coronavirus Clinical Characterisation Consortium. We thank Kate Holmes at the NIHR Office for Clinical Research Infrastructure (NOCRI) for her support in coordinating the charities group. The PHOSP-COVID industry framework was formed to provide advice and support in commercial discussions, and we thank the Association of the British Pharmaceutical Industry as well NOCRI for coordinating this. We are very grateful to all the charities that have provided insight to the study: Action Pulmonary Fibrosis, Alzheimer's Research UK, Asthma + Lung UK, British Heart Foundation, Diabetes UK, Cystic Fibrosis Trust, Kidney Research UK, MQ Mental Health, Muscular Dystrophy UK, Stroke Association Blood Cancer UK, McPin Foundations, and Versus Arthritis. We thank the NIHR Leicester Biomedical Research Centre patient and public involvement group and Long Covid Support.

Table 1: Baseline characteristics after propensity weighting.

Data are n, n (%) or mean (SD). Percentages are calculated by category after exclusion of missing data for that variable. SD = standard deviation. IMD = Index of Multiple Deprivation. WHO = World Health Organisation. SMD = Standardised Mean Difference

Characteristic		Corticosteroids	No corticosteroids	SMD
n		1147.93	740.15	
Age at admission, years (mean (SD))		58.52 (11.89)	58.50 (12.60)	0.002
Sex (%)	Male	741.6 (64.6)	479.2 (64.7)	0.003
	Female	406.3 (35.4)	261.0 (35.3)	
Ethnicity (%)	White	862.8 (75.2)	558.3 (75.4)	0.008
	South Asian	118.2 (10.3)	76.2 (10.3)	
	Black	83.5 (7.3)	53.4 (7.2)	
	Other	83.4 (7.3)	52.3 (7.1)	
IMD quintile (%)	1 - most deprived	262.4 (22.9)	169.1 (22.9)	0.008
	2	269.6 (23.5)	172.6 (23.3)	
	3	202.5 (17.6)	132.8 (17.9)	
	4	196.2 (17.1)	126.6 (17.1)	
	5 - least deprived	217.1 (18.9)	139.0 (18.8)	
Obesity (%)	Yes	683.3 (59.5)	440.1 (59.5)	0.001
	No	464.6 (40.5)	300.0 (40.5)	
Smoking status (%)	Never	642.7 (56.0)	412.0 (55.7)	0.007
	Ex-smoker	484.6 (42.2)	314.3 (42.5)	
	Current smoker	20.7 (1.8)	13.8 (1.9)	
Number of comorbidities		1.48 (1.37)	1.49 (1.40)	0.005
Number of comorbidities (%)	No comorbidity	342.2 (29.8)	222.1 (30.0)	0.013
	1 comorbidity	308.5 (26.9)	202.2 (27.3)	
	2+ comorbidities	497.2 (43.3)	315.8 (42.7)	
Cardiovascular comorbidities (%)	Yes	562.6 (49.0)	361.6 (48.9)	0.003
	No	585.4 (51.0)	378.6 (51.1)	
Metabolic/endocrine/renal comorbidities (%)	Yes	314.7 (27.4)	198.8 (26.9)	0.012
	No	833.2 (72.6)	541.4 (73.1)	
Respiratory comorbidities (%)	Yes	292.3 (25.5)	190.1 (25.7)	0.005
	No	855.6 (74.5)	550.1 (74.3)	
Type 2 diabetes (%)	Yes	238.5 (20.8)	151.4 (20.5)	0.008
	No	909.4 (79.2)	588.8 (79.5)	
Neurological/psychiatric comorbidities (%)	Yes	52.1 (4.5)	31.8 (4.3)	0.012
	No	1095.8 (95.5)	708.4 (95.7)	

It is made available under a [CC-BY 4.0 International license](#) .

WHO clinical progression scale status (%)	WHO scale 5	603.3 (52.6)	388.1 (52.4)	0.002
	WHO scale 6	335.0 (29.2)	216.3 (29.2)	
	WHO scale 7-9	209.6 (18.3)	135.7 (18.3)	

Table 2: Primary and secondary outcomes: patient reported outcomes, mental health status and cognitive assessments.

Data are n, n (%), mean (SD) or median (IQR). Percentages are calculated by category after exclusion of missing data for that variable. SD = standard deviation, IQR = interquartile range, EQ-5D-5L UI = EuroQol-5-Dimension 5-level utility index, VAS = visual analogue scale, FACIT = Functional Assessment of Chronic Illness Therapy, MoCA = Montreal Cognitive Assessment, WG-SS = Washington Group Short Set, GAD-7 = Generalized Anxiety Disorder 7-item score, PHQ-8 = Patient Health Questionnaire-8, PCL-5 = Post-Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders, PTSD = post-traumatic stress disorder

Outcome		Corticosteroids	No corticosteroids	p-value
n		737.5	488.9	
EQ-5D-5L UI at 1 year (mean (SD))		0.72 (0.25)	0.71 (0.25)	0.773
EQ-5D-5L UI change pre-hospital to 1 year (mean (SD))		-0.11 (0.22)	-0.12 (0.22)	0.317
Do you feel fully recovered from covid? (n (%))	Yes	223.1 (30.2)	139.1 (28.5)	0.811
	No/not sure	465.3 (63.1)	299.6 (61.3)	
	Missing	49.2 (6.7)	50.2 (10.3)	
Any symptom at 1 year (n (%))	Yes	656.8 (89.1)	423.6 (86.6)	0.508
	No	39.9 (5.4)	21.4 (4.4)	
	Missing	40.8 (5.5)	43.9 (9.0)	
Symptom count (median [IQR])		8.00 [4.00, 16.00]	9.00 [4.00, 16.00]	0.671
Fatigue VAS		2.00 [0.00, 5.00]	3.00 [0.00, 5.00]	0.465
Breathlessness VAS		1.00 [0.00, 4.00]	1.00 [0.00, 5.00]	0.043
Dyspnoea-12 score (mean (SD))		5.04 (7.22)	5.46 (7.83)	0.373
FACIT fatigue score (mean (SD))		36.79 (12.23)	36.31 (12.87)	0.524
MoCA corrected (mean (SD))		26.90 (3.22)	26.65 (3.23)	0.232
MoCA corrected <23 (n (%))	Yes	49.6 (6.7)	41.7 (8.5)	0.373
	No	516.8 (70.1)	356.6 (72.9)	
	Missing	171.1 (23.2)	90.6 (18.5)	
WG-SS score (median [IQR])		2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.613
GAD-7 total score (mean (SD))		4.75 (5.46)	4.91 (5.60)	0.631
Anxiety (GAD-7 score >8) (n (%))	Yes	159.6 (21.6)	110.5 (22.6)	0.684
	No	576.0 (78.1)	375.8 (76.9)	
	Missing	< 5	< 5	
PHQ-8 total score (mean (SD))		6.14 (6.25)	6.21 (6.39)	0.791
PCL-5 total score (mean (SD))		13.63 (16.76)	13.76 (17.54)	0.901
PTSD (PCL-5 score >=38) (n (%))	Yes	79.6 (10.8)	51.0 (10.4)	0.866
	No	650.8 (88.2)	431.1 (88.2)	
	Missing	7.1 (1.0)	6.7 (1.4)	

Table 3: Secondary outcomes: physical impairment and organ function.

Data are n, n (%) or mean (SD). Percentages are calculated by category after exclusion of missing data for that variable. SD = standard deviation, ISWT = incremental shuttle walk test, SPPB = short physical performance battery, FEV1 = forced expiratory volume, FVC = forced vital capacity, KCO = carbon monoxide transfer coefficient, TLCO = transfer capacity of the lung, BNP = brain natriuretic peptide, eGFR = estimated glomerular filtration rate

Outcome		Corticosteroids	No corticosteroids	P-value
n		737.5	488.9	
ISWT distance, m (mean (SD))		462.78 (468.30)	455.15 (252.13)	0.770
ISWT % predicted (mean (SD))		62.59 (59.25)	60.59 (28.72)	0.604
SPPB total score (mean (SD))		10.12 (1.99)	9.93 (2.32)	0.160
SPPB (mobility disability ≤10) (n (%))	Yes	289.4 (39.2)	219.0 (44.8)	0.671
	No	325.1 (44.1)	233.1 (47.7)	
	Missing	122.9 (16.7)	36.8 (7.5)	
FEV1 % predicted <80% (n (%))	Yes	78.1 (10.6)	70.3 (14.4)	0.613
	No	258.1 (35.0)	210.6 (43.1)	
	Missing	401.3 (54.4)	208.0 (42.5)	
FVC % predicted <80% (n (%))	Yes	85.1 (11.5)	74.3 (15.2)	0.772
	No	251.1 (34.0)	207.3 (42.4)	
	Missing	401.3 (54.4)	207.3 (42.4)	
FEV1/FVC <0.7 (n (%))	Yes	32.5 (4.4)	31.1 (6.4)	0.606
	No	310.6 (42.1)	257.8 (52.7)	
	Missing	394.4 (53.5)	200.0 (40.9)	
KCO <80% predicted (n (%))	Yes	15.6 (2.1)	9.3 (1.9)	0.287
	No	103.6 (14.0)	98.0 (20.1)	
	Missing	618.3 (83.8)	381.6 (78.0)	
TLCO <80% predicted (n (%))	Yes	19.2 (2.6)	27.7 (5.7)	0.074
	No	92.4 (12.5)	71.4 (14.6)	
	Missing	625.8 (84.9)	389.8 (79.7)	
BNP ≥100 ng/L or pro-NT-BNP ≥400 ng/L	Yes	23 (3.2)	24 (4.9)	0.529
	No	292 (39.9)	229 (46.3)	
	Missing	416 (56.9)	242 (48.9)	
HbA1C ≥6.0% (DCCT/NGSP)	Yes	157 (21.5)	114 (23.0)	0.881
	No	277 (37.9)	196 (39.6)	
	Missing	297 (40.6)	185 (37.4)	
eGFR <60 mL/min per 1.73 m ²	Yes	74 (10.1)	63 (12.7)	0.586
	No	475 (65.0)	321 (64.8)	
	Missing	182 (24.9)	111 (22.4)	
C-reactive protein concentration >5 mg/L	Yes	124 (17.0)	78 (15.8)	0.204
	No	423 (57.9)	321 (64.8)	
	Missing	184 (25.2)	96 (19.4)	
Fibrinogen (g/L) (mean (SD))		3.58 (2.23)	3.56 (0.87)	0.846

Figure 1: Consort diagram demonstrating study population included in co-primary outcomes of i) EQ-5D-5L UI at one year (A) and ii) change in EQ-5D-5L UI from pre-hospital to one year (B), and sensitivity analysis (C).




Figure 2: EQ-5D-5L UI at one year after hospital discharge in corticosteroid exposed vs non-exposed patients.




Figure 3: EQ-5D-5L UI change from pre-hospital (baseline) to one year in corticosteroid exposed vs non-exposed patients.





Figure 4: Secondary outcomes: patient-perceived recovery (A), Short Physical Performance Battery score (B), symptom count (C) and Montreal Cognitive Assessment score (corrected) (D) one year after hospital discharge in corticosteroid exposed vs non-exposed patients.



References

1. Horby, P., Lim, W.S., Emberson, J.R., et al., *Dexamethasone in Hospitalized Patients with Covid-19*. N Engl J Med, 2021. **384**(8): p. 693-704.
2. RECOVERY Collaborative Group, *Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial*. Lancet, 2021. **397**(10285): p. 1637-1645.
3. RECOVERY Collaborative Group, *Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial*. Lancet, 2022. **399**(10325): p. 665-676.
4. RECOVERY Collaborative Group, *Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis*. Lancet, 2022. **400**(10349): p. 359-368.
5. Evans, R.A., McAuley, H., Harrison, E.M., et al., *Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study*. Lancet Respir Med, 2021. **9**(11): p. 1275-1287.
6. PHOSP-COVID Collaborative Group, *Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study*. Lancet Respir Med, 2022(S2213-2600(22)00127-8).
7. Huang, L., Li, X., Gu, X., et al., *Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study*. Lancet Respir Med, 2022. **10**(9): p. 863-876.
8. National Institute for Health and Care Excellence. *COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188]*. 2020 Updated 11/11/21 [Accessed 22/10/23]].
9. World Health Organisation. *Post COVID-19 condition (Long COVID)*. 2022 07/12/22 [Accessed 22/10/23]].
10. Perego, E., Callard, F., Stras, L., et al., *Why the Patient-Made Term 'Long Covid' is needed*. Wellcome Open Research, 2020. **5**(224).
11. Davis, H.E., McCorkell, L., Vogel, J.M., et al., *Long COVID: major findings, mechanisms and recommendations*. Nat Rev Microbiol, 2023. **21**(3): p. 133-146.
12. Higgins, A.M., Berry, L.R., Lorenzi, E., et al., *Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial*. Jama, 2023. **329**(1): p. 39-51.
13. Elneima, O., McAuley, H.J.C., Leavy, O.C., et al., *Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)*. medRxiv, 2023: p. 2023.05.08.23289442.
14. International Severe Acute Respiratory and emerging Infection Consortium. *ISARIC: COVID-19 Clinical research resources*. 2023 [Accessed 22/08/23]].
15. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, *A minimal common outcome measure set for COVID-19 clinical research*. Lancet Infect Dis, 2020. **20**(8): p. e192-e197.
16. National Institute for Health and Care Excellence. *COVID-19 rapid guideline: Managing COVID-19*. 2022 Updated 15/06/22 [Accessed 28/10/23]].
17. Herdman, M., Gudex, C., Lloyd, A., et al., *Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)*. Qual Life Res, 2011. **20**(10): p. 1727-36.
18. Yorke, J., Moosavi, S.H., Shuldham, C., et al., *Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12*. Thorax, 2010. **65**(1): p. 21-6.

19. Yellen, S.B., Cella, D.F., Webster, K., et al., *Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system*. J Pain Symptom Manage, 1997. **13**(2): p. 63-74.
20. Madans, J.H., Loeb, M.E., Altman, B.M., *Measuring disability and monitoring the UN Convention on the Rights of Persons with Disabilities: the work of the Washington Group on Disability Statistics*. BMC Public Health, 2011. **11 Suppl 4**(Suppl 4): p. S4.
21. Singh, S.J., Morgan, M.D., Scott, S., et al., *Development of a shuttle walking test of disability in patients with chronic airways obstruction*. Thorax, 1992. **47**(12): p. 1019-24.
22. Guralnik, J.M., Simonsick, E.M., Ferrucci, L., et al., *A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission*. J Gerontol, 1994. **49**(2): p. M85-94.
23. Nasreddine, Z.S., Phillips, N.A., Bédirian, V., et al., *The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment*. J Am Geriatr Soc, 2005. **53**(4): p. 695-9.
24. Johnson, S.U., Ulvenes, P.G., Øktedalen, T., et al., *Psychometric Properties of the General Anxiety Disorder 7-Item (GAD-7) Scale in a Heterogeneous Psychiatric Sample*. Front Psychol, 2019. **10**: p. 1713.
25. Levis, B., Benedetti, A., Thombs, B.D., *Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis*. Bmj, 2019. **365**: p. l1476.
26. Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., & Schnurr, P.P. . *The PTSD Checklist for DSM-5 (PCL-5)*. 2013; Available from: Scale available from the National Center for PTSD at www.ptsd.va.gov.
27. McNamara, S., Schneider, P.P., Love-Koh, J., et al., *Quality-Adjusted Life Expectancy Norms for the English Population*. Value Health, 2023. **26**(2): p. 163-169.
28. Nolan, C.M., Longworth, L., Lord, J., et al., *The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference*. Thorax, 2016. **71**(6): p. 493-500.
29. Granholm, A., Kjær, M.N., Munch, M.W., et al., *Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia*. Intensive Care Med, 2022. **48**(5): p. 580-589.
30. Boglione, L., Meli, G., Poletti, F., et al., *Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?* Qjm, 2022. **114**(12): p. 865-871.
31. Monk, P.D., Evans, R.A., Tear, V.J., et al., *LB1533. Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial*. Open Forum Infectious Diseases, 2022. **9**(Supplement_2).
32. Bramante, C.T., Buse, J.B., Liebovitz, D.M., et al., *Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial*. Lancet Infect Dis, 2023. **23**(10): p. 1119-1129.
33. Toshner, M.R., Gamble, C., Baillie, J.K., et al., *Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial*. medRxiv, 2022: p. 2022.12.07.22283175.
34. HEAL-COVID. *HEAL-COVID study*. [Accessed 22/10/23]; Available from: <https://heal-covid.net/>.
35. Finnigan, L.E.M., Cassar, M.P., Koziel, M.J., et al., *Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study*. EClinicalMedicine, 2023. **59**: p. 101946.
36. Ramasawmy, M., Mu, Y., Clutterbuck, D., et al., *STIMULATE-ICP-CAREINEQUAL (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study protocol: Defining usual care and examining inequalities in Long Covid support*. PLoS One, 2022. **17**(8): p. e0271978.

37. PHOSP-COVID. *The Post-hospitalisation COVID-19 study*. [Accessed 03/10/2023]]; Available from: <https://phosp.org/>.